Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Rituximab, Venetoclax, and Chemotherapy in Newly Diagnosed Mantle Cell Lymphoma (Window II)
NCT03710772Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, venetoclax in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2019; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03710772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710772.